This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignee: Mesoblast International Sarl. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: Lee Golden: Innovator in Heart Failure Treatments
Introduction
Lee Golden is a notable inventor based in New York, NY, who has made significant contributions to the field of medical treatments for heart failure. With a total of four patents to his name, Golden's work focuses on innovative methods to improve the lives of patients suffering from chronic heart conditions.
Latest Patents
Golden's latest patents include a method for treating heart failure, which involves the use of STRO-1+ mesenchymal lineage precursor cells (MPCs) to address left ventricular end systolic (LVESV) dysfunction. This groundbreaking approach aims to enhance the treatment of chronic heart failure. Another significant patent is related to the prevention of progressive heart failure. This method is designed for subjects with persistent left ventricular dysfunction and can also be utilized for treating or preventing progressive heart failure in patients with a proximal left anterior descending (LAD) lesion.
Career Highlights
Throughout his career, Lee Golden has worked with prominent companies in the medical field, including Mesoblast International Sarl and Mesoblast International Sàrl. His expertise and innovative approaches have positioned him as a key figure in the development of advanced heart failure treatments.
Collaborations
Golden has collaborated with notable professionals in his field, including Silviu Itescu, who has contributed to the advancement of heart treatment methodologies.
Conclusion
Lee Golden's contributions to heart failure treatments through his innovative patents and collaborations highlight his commitment to improving patient outcomes. His work continues to pave the way for advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile